High Volume Saline Injections for Achilles Tendinopathy
Achilles Tendinopathy
About this trial
This is an interventional treatment trial for Achilles Tendinopathy focused on measuring Achilles, Tendinopathy, Tendonitis, Injection
Eligibility Criteria
Inclusion Criteria:
- Age 18+
- More than 13 weeks of pain in the achilles tendon area
- Completed eccentric tendon loading programme with a physiotherapist
- Achilles tendon tender to palpation in the midportion
- Tendon diameter greater than 0.7cm on ultrasound scan
- Evidence of neovascularisation on doppler ultrasound scan
- Sufficient English language to complete questionnaires and consent
Exclusion Criteria:
- Ultrasound evidence or previous history of partial or full tendon tear
- Another co-existing significant foot or ankle pathology
- Taking anticoagulant medication i.e: warfarin, clopidogrel, dipyridamole
- A medical condition that would affect safety of injection i.e. diabetic neuropathy, peripheral vascular disease
- Previous achilles tendon surgery
- unable to give informed consent
Sites / Locations
- Leeds Musculoskeletal and Rehabilitation ServiceRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
High volume saline injection
Control Arm
Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises. Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks